Close Menu

NEW YORK (GenomeWeb) – OncoCyte reported after the close of the market on Monday that its fourth quarter net loss grew 29 percent year over year as it continues to prepare to commercialize its first test by the end of 2018.

The liquid biopsy firm's net loss for the three-month period ended Dec. 31 was $4.0 million, or $.13 per share, compared to a net loss of $3.1 million, or $.11 per share, in the fourth quarter of 2016. The company matched analyst expectations for a net loss of $.13 per share.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sep
30
Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Oct
09
Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.